AU2023237900A1 - Tyk2 inhibitors and uses thereof - Google Patents

Tyk2 inhibitors and uses thereof Download PDF

Info

Publication number
AU2023237900A1
AU2023237900A1 AU2023237900A AU2023237900A AU2023237900A1 AU 2023237900 A1 AU2023237900 A1 AU 2023237900A1 AU 2023237900 A AU2023237900 A AU 2023237900A AU 2023237900 A AU2023237900 A AU 2023237900A AU 2023237900 A1 AU2023237900 A1 AU 2023237900A1
Authority
AU
Australia
Prior art keywords
compound
patient
psoriasis
hours
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023237900A
Other languages
English (en)
Inventor
Alan John Collis
Vinayak Hosagrahara
Bhaskar SRIVASTAVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2023237900A1 publication Critical patent/AU2023237900A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023237900A 2022-03-25 2023-03-24 Tyk2 inhibitors and uses thereof Pending AU2023237900A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263269943P 2022-03-25 2022-03-25
US63/269,943 2022-03-25
US202263371033P 2022-08-10 2022-08-10
US63/371,033 2022-08-10
US202363490664P 2023-03-16 2023-03-16
US63/490,664 2023-03-16
PCT/US2023/064902 WO2023183901A1 (en) 2022-03-25 2023-03-24 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2023237900A1 true AU2023237900A1 (en) 2024-10-10

Family

ID=88102041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023237900A Pending AU2023237900A1 (en) 2022-03-25 2023-03-24 Tyk2 inhibitors and uses thereof

Country Status (10)

Country Link
US (1) US20250213572A1 (enExample)
EP (1) EP4499104A4 (enExample)
JP (1) JP2025510813A (enExample)
KR (1) KR20240165963A (enExample)
AU (1) AU2023237900A1 (enExample)
CA (1) CA3246157A1 (enExample)
CL (1) CL2024002824A1 (enExample)
MX (1) MX2024011693A (enExample)
TW (1) TW202345799A (enExample)
WO (1) WO2023183901A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263861A2 (en) * 2023-06-23 2024-12-26 Dana-Farber Cancer Institute, Inc. Methods of treating chronic lymphocytic leukemia
EP4780462A1 (en) * 2023-09-21 2026-07-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN122341608A (zh) * 2023-11-24 2026-07-03 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2026032374A1 (zh) * 2024-08-07 2026-02-12 正大天晴药业集团股份有限公司 含联环的化合物用于治疗银屑病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
MX2024011693A (es) 2024-11-08
US20250213572A1 (en) 2025-07-03
CA3246157A1 (en) 2023-09-28
EP4499104A1 (en) 2025-02-05
JP2025510813A (ja) 2025-04-15
EP4499104A4 (en) 2025-09-03
KR20240165963A (ko) 2024-11-25
TW202345799A (zh) 2023-12-01
CL2024002824A1 (es) 2025-02-14
WO2023183901A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20250213572A1 (en) Tyk2 inhibitors and uses thereof
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
US12338242B2 (en) TYK2 inhibitors and uses thereof
TWI783978B (zh) Tyk2抑制劑、其用途及生產方法
JP2025534698A (ja) Ｉｒａｋ４デグレーダーの塩の形態
JP2024506858A (ja) Ｇｐｒ８４アンタゴニストおよびその使用
WO2024064080A1 (en) Stat6 degraders and uses thereof
US20240262830A1 (en) Ire1a modulators and uses thereof
US20250215002A1 (en) Solid forms of tyk2 inhibitors and methods of use
WO2024028365A1 (en) Substituted pyridone gpr84 antagonists and uses thereof
AU2023317741A1 (en) Aryl-triazolyl and related gpr84 antagonists and uses thereof
US20250206743A1 (en) Tyk2 inhibitor synthesis and intermediates thereof
US20250221997A1 (en) Tyk2 inhibitor formulations and methods of making the same
AU2023317740A1 (en) Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
EP4452940A1 (en) Oxer1 antagonists and uses thereof
CN118973583A (zh) Tyk2抑制剂及其用途
WO2025062372A1 (en) Tyk2 inhibitors for use in the treatment of inflammatory bowel disease